Stella Diagnostics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SLDX research report →
About the company
Stella Diagnostics Inc. is a molecular diagnostics firm primarily focused on advancing patient care strategies for individuals afflicted with severe esophageal disorders. The company's specialized clinical tests furnish physicians with crucial information regarding the molecular makeup of a patient's tissue, enabling them to ascertain if the disease is static, deteriorating, or undergoing malignant transformation.
- CEO
- David Seaburg
- IPO
- 2021
- Employees
- 2
- HQ
- Salt Lake City, UT, US
Price Chart
- Market Cap
- $1.01M
- P/E
- -0.86
- P/S
- 0.56
- P/B
- -0.12
- EV/EBITDA
- -3.83
- Div Yield
- 0.00%
- Gross Margin
- -40.44%
- Op Margin
- -196.67%
- Net Margin
- -227.47%
- ROE
- 17.12%
- ROIC
- 24.37%
- Revenue
- $1.78M · 0.00%
- Net Income
- $-4,057,706 · -228.38%
- EPS
- $-0.01 · -277.42%
- Op Income
- $-3,447,083
- FCF YoY
- -2151.47%
- 52W High
- $0.05
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.02
- Beta
- -0.23
- Avg Volume
- 247
Get TickerSpark's AI analysis on SLDX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our SLDX coverage
Recent articles, reports, and earnings notes.
No research on SLDX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SLDX report →Similar companies
Peers in the same neighborhood.